BioVaxys is planning to request that its investigational vaccine for ovarian cancer, BVX-0918A, be approved for compassionate use in people with advanced ovarian cancer in Europe. The company also plans to file requests to U.S. and European regulatory health authorities requesting authorization to pursue clinical trials of BVX-0918A in the coming months. As part of its plan to accelerate the development of BVX-0918A, BioVaxys is already having discussions with its designated contract manufacturing organization, and…
You must be logged in to read/download the full post.
The post BioVaxys Advances Plans to Bring Vaccine to Clinic appeared first on BioNewsFeeds.